. 2023 Apr 13;18(6):727–738. doi: 10.2215/CJN.0000000000000135

Table 2.

Clinical outcomes of proteinuria analysis in population 1

Proteinuria Analysis Population 1
Time-Averaged Proteinuria^a Duration		Total				0–24 Months
Time-Averaged Proteinuria Category	Overall	<0.44 g/g	0.44 to <0.88 g/g	0.88 to <1.76 g/g	≥1.76 g/g	<0.44 g/g	0.44 to <0.88 g/g	0.88 to <1.76 g/g	≥1.76 g/g
Survival rate, estimate (95% CI)	n=887	n=215^b	n=175^b	n=251	n=246	n=247^b	n=168^b	n=230	n=242
10-yr	0.46 (0.41 to 0.51)	0.78 (0.68 to 0.85)^b	0.69 (0.56 to 0.79)^b	0.40 (0.31 to 0.48)	0.15 (0.09 to 0.22)	0.70 (0.61 to 0.78)^b	0.57 (0.44 to 0.68)^b	0.36 (0.26 to 0.47)	0.24 (0.17 to 0.32)
Kidney failure risk (10-yr), Cox regression, HR (95% Wald CL)
Unadjusted	N/A	Reference^b	1.26 (0.78 to 2.01)^b	3.08 (2.09 to 4.5)	7.00 (4.81 to 10.09)	Reference^b	1.42 (0.94 to 2.14)^b	2.81 (2.00 to 3.95)	5.46 (3.95 to 7.55)
Adjusted	N/A	Reference^b	1.07 (0.64 to 1.79)^b	2.73 (1.78 to 4.16)	7.66 (5.09 to 11.52)	Reference^b	1.32 (0.85 to 2.04)^b	2.65 (1.79 to 3.92)	5.73 (3.92 to 8.38)
eGFR slope, total (ml/min per 1.73 m² per year), mean (SD)	n=887	n=215^b	n=175^b	n=251	n=246	n=247^b	n=168^b	n=230	n=242
Mean (SD)	−3.7 (8.1)	−0.0 (7.3)^b	−1.1 (5.7)^b	−3.8 (5.5)	−9.5 (9.4)	−0.6 (7.1)^b	−1.9 (5.9)^b	−3.8 (6.3)	−8.7 (9.6)
Median (IQR)	−2.6 (−6.0 to −0.4)	−0.3 (−1.8 to 1.2)^b	−1.6 (−2.9 to −0.1)^b	−3.3 (−5.7 to −1.3)	−7.3 (−12.3 to −3.4)	−0.9 (−2.6 to 0.7)^b	−1.7 (−3.9 to −0.1)^b	−3.3 (−6.0 to −1.2)	−6.4 (−12.2 to −2.7)

CI, confidence interval; HR, hazard ratio; CL, confidence limit; NA, not available; IQR, interquartile range.

0.44 g/g=50 mg/mmol (approximately 0.5 g/d); 0.88 g/g=100 mg/mmol (approximately 1 g/d); 1.76 g/g=200 mg/mmol (approximately 2 g/d).

Represent patients who would be classified as low-risk disease progression (proteinuria of <1 g/d) as termed by Kidney Disease Improving Global Outcomes.¹¹